Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4‐RD and DLBCL
Immunity, Inflammation and Disease · 2026
DOI: 10.1002/iid3.70529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Yongkang Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical College, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunoglobulin G4-Related Disease, Nomograms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the Clinical Research Program of the Affiliated Hospital of Xuzhou Medical University, Clinical Research Program of the Affiliated Hospital of Xuzhou Medical University.
Abstract (Originalsprache)
Objective
To determine clinically useful indicators that distinguish IgG4‐related disease (IgG4‐RD) from diffuse large B‐cell lymphoma (DLBCL) and to construct a predictive model that may assist early identification.
Methods
We retrospectively analyzed 19 patients with IgG4‐RD and 37 with DLBCL who presented with lymphadenopathy and received treatment at the Affiliated Hospital of Xuzhou Medical University between January 2012 and October 2025. The distribution of continuous variables was checked before group comparisons. Data with an approximately normal distribution are expressed as mean ± standard deviation (mean ± SD) and were compared by independent‐samples t ‐tests; skewed data are reported as median (interquartile range [IQR]) and were compared by the Mann‐Whitney U test. Categorical variables are presented as counts and percentages (%) and were compared using the χ 2 test or Fisher's exact test, as appropriate. Variables significant in univariate analyses were taken forward into multivariable logistic regression. Predictive performance was evaluated by receiver operating characteristic (ROC) analysis, calibration analysis, and decision curve analysis (DCA).
Results
Multivariable logistic regression retained lymphocyte count, serum total protein, and prothrombin time (PT) as independent predictive factors. The model yielded an area under the receiver operating characteristic curve (AUC) of 0.91 (95% confidence interval [CI]: 0.82–0.99). Its calibration curve had a mean absolute error of 0.032. Across threshold probabilities from 0.2 to 1.0, decision curve analysis indicated greater net benefit than the “treat‐all” and “treat‐none” approaches.
Conclusion
In this cohort, the predictive model showed potential to assist differentiation between IgG4‐RD and DLBCL. Because the study was retrospective, single‐center, and based on a limited sample, these findings should be regarded as preliminary and require confirmation in larger independent cohorts before clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical College, Xuzhou Medical University, Xuzhou, China.
- Rheumatology and Immunology Department, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Weimiao Li, Jiqing Wu, Dongmei Zhou
Förderung
- This study was supported by the Clinical Research Program of the Affiliated Hospital of Xuzhou Medical University
- Clinical Research Program of the Affiliated Hospital of Xuzhou Medical University
Zitieren
APA
Chen, Y., Li, W., Zhou, Z., Wu, J., & Zhou, D. (2026). Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4‐RD and DLBCL. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70529
Vancouver
Chen Y, Li W, Zhou Z, Wu J, Zhou D. Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4‐RD and DLBCL. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70529
BibTeX
@article{Chen2026,
author = {Chen, Yongkang and Li, Weimiao and Zhou, Zhou and Wu, Jiqing and Zhou, Dongmei},
title = {Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4‐RD and DLBCL},
journal = {Immunity, Inflammation and Disease},
year = {2026},
doi = {10.1002/iid3.70529}
}
EUVIMED